Gene context drift identifies drug targets to mitigate cancer treatment resistance

Cancer Cell. 2025 Sep 8;43(9):1608-1621.e9. doi: 10.1016/j.ccell.2025.06.005. Epub 2025 Jun 26.

Abstract

Cancer treatment often fails because combinations of different therapies evoke complex resistance mechanisms that are hard to predict. We introduce REsistance through COntext DRift (RECODR): a computational pipeline that combines co-expression graph networks of single-cell RNA sequencing profiles with a graph-embedding approach to measure changes in gene co-expression context during cancer treatment. RECODR is based on the idea that gene co-expression context, rather than expression level alone, reveals important information about treatment resistance. Analysis of tumors treated in preclinical and clinical trials using RECODR unmasked resistance mechanisms -invisible to existing computational approaches- enabling the design of highly effective combination treatments for mice with choroid plexus carcinoma, and the prediction of potential new treatments for patients with medulloblastoma and triple-negative breast cancer. Thus, RECODR may unravel the complexity of cancer treatment resistance by detecting context-specific changes in gene interactions that determine the resistant phenotype.

Keywords: DNA repair; cancer; choroid plexus; choroid plexus carcinoma; combination therapy; graph networks; machine learning; radiation; treatment resistance; triple-negative breast cancer.

MeSH terms

  • Animals
  • Drug Resistance, Neoplasm* / genetics
  • Female
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Regulatory Networks
  • Humans
  • Medulloblastoma / drug therapy
  • Medulloblastoma / genetics
  • Mice
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • Single-Cell Analysis
  • Triple Negative Breast Neoplasms / drug therapy
  • Triple Negative Breast Neoplasms / genetics